BeStock  
Stocks › Biotechnology › AGIO

Agios Pharmaceuticals AGIO

US equityMarket cap rank #2807Biotechnology
$27.60 −$1.16 (-4.03%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $27.60 0.00%
Open$28.01
Prev close$28.76
Day range$27.43 – $29.14
Volume776.2K
Market cap$1.65B
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership117.2%+4.99 pts vs. prior quarter
Institutions holding295+10 vs. prior quarter
Insider trades (recent)37 buys / 13 sellsNet buying
Short interest10.93% of floatDays to cover 5.2 · as of 30 Oct 2026
Short-sale volume share23.7%5-day average of daily volume

Short-sale volume as % of daily volume

9%19%29%40%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: +$4.75M (9 inflow days, 11 outflow days).

Net flow by order size, last 20 sessions

−$1.2MSuper+$6.0MBig+$2.1MMid+$6.5MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 37.2% of shares outstanding.

Largest holders

  • BlackRock10.42%
  • Farallon Capital Management, L.L.C.9.89%
  • Morgan Stanley5.75%
  • Lynx1 Capital Management LP5.70%
  • State Street Global Advisors5.46%
  • D. E. Shaw & Co., L.P.5.19%
  • Vanguard Portfolio Management, LLC4.77%
  • Vanguard Capital Management, LLC4.49%

By investor type

  • Mutual Fund67.72%
  • Hedge Fund34.00%
  • Public Company8.36%
  • Private Company4.41%
  • VC/PE Fund1.31%
  • Individual/Insider1.11%
  • Insurance Company0.93%
  • Government Pension Fund0.43%

Reported short interest has fallen from 12.78% to 10.93% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
Morgan Stanley Public Company 2026/Q3 +2,473,333 5.7%
Assenagon Asset Management S.A. Mutual Fund 2026/Q3 +1,782,457 3.2%
Renaissance Technologies Corp. Hedge Fund 2026/Q3 +505,600 0.8%
GW&K Investment Management, LLC Mutual Fund 2026/Q3 +189,815 2.3%
ADAR1 Capital Management, LLC Hedge Fund 2026/Q3 +1,147,381 2.2%
UBS Asset Management Mutual Fund 2026/Q3 +859,521 1.8%
Lynx1 Capital Management LP Mutual Fund 2026/Q3 +797,369 5.7%
BlackRock Mutual Fund 2026/Q3 +701,040 10.8%
AQR Capital Management Hedge Fund 2026/Q3 +640,748 1.1%
Macquarie Investment Management Business Trust Mutual Fund 2026/Q3 +616,374 3.5%
Arrowstreet Capital, Limited Partnership Mutual Fund 2026/Q3 +560,069 1.4%
Defilade Capital Management, L.P. Hedge Fund 2026/Q3 +546,848 0.9%
Point72 Asset Management, L.P. Hedge Fund 2026/Q3 +506,344 0.8%
D. E. Shaw & Co., L.P. Hedge Fund 2026/Q3 +425,836 5.2%
Qube Research & Technologies Ltd Mutual Fund 2026/Q3 +409,971 1.0%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
25 Oct 2026 Sarah Gheuens Chief Medical Officer and Head of Research & Development Intent to Sell (Form 144) -7,866 $37.69 –
25 Oct 2026 Sarah Gheuens Chief Medical Officer and Head of Research & Development Derivative Exercise and Sale -7,866 $37.69 54,645
21 Oct 2026 Sarah Gheuens Chief Medical Officer and Head of Research & Development Intent to Sell (Form 144) -500 $37.52 –
21 Oct 2026 Sarah Gheuens Chief Medical Officer and Head of Research & Development Derivative Exercise and Sale -1,989 $37.53 54,645
20 Oct 2026 Sarah Gheuens Chief Medical Officer and Head of Research & Development Intent to Sell (Form 144) -1,489 $37.53 –
3 Aug 2026 Sarah Gheuens Chief Medical Officer and Head of Research & Development Automatic Disposition -30,000 $30.48 54,645
7 Jul 2026 Jay Backstrom Independent Director Other Acquisition +1,447 – 1,447
30 Jun 2026 Sarah Gheuens Chief Medical Officer and Head of Research & Development Derivative Exercise and Sale -4,007 $37.56 84,645
30 Jun 2026 Sarah Gheuens Chief Medical Officer and Head of Research & Development Derivative Exercise and Retained +4,368 – 84,645
17 Jun 2026 Jacqualyn Fouse Chair of the Board of Directors Other Derivative Acquisition +2,927 – 2,927
17 Jun 2026 Jacqualyn Fouse Chair of the Board of Directors Other Derivative Acquisition +14,950 $34.16 14,950
17 Jun 2026 Jacqualyn Fouse Chair of the Board of Directors Derivative Exercise and Retained +2,816 – 154,156
17 Jun 2026 Jeffrey Capello Independent Director Other Derivative Acquisition +2,927 – 2,927
17 Jun 2026 Jeffrey Capello Independent Director Other Derivative Acquisition +14,950 $34.16 14,950
17 Jun 2026 Jeffrey Capello Independent Director Derivative Exercise and Retained +2,816 – 10,865
17 Jun 2026 Kaye Foster-Cheek Lead Independent Director Other Derivative Acquisition +2,927 – 2,927
17 Jun 2026 Kaye Foster-Cheek Lead Independent Director Other Derivative Acquisition +14,950 $34.16 14,950
17 Jun 2026 Kaye Foster-Cheek Lead Independent Director Derivative Exercise and Retained +2,816 – 12,484
17 Jun 2026 Jay Backstrom Independent Director Other Derivative Acquisition +2,927 – 2,927
17 Jun 2026 Jay Backstrom Independent Director Other Derivative Acquisition +14,950 $34.16 14,950

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 6,524,140 10.9% 5.2
15 Oct 2026 6,894,856 11.5% 5.6
30 Sep 2026 7,016,166 11.8% 6.4
15 Sep 2026 7,557,252 12.7% 9.5
31 Aug 2026 7,535,054 12.6% 8.4
14 Aug 2026 7,629,012 12.8% 7.0

Discussion

No comments yet — be the first to weigh in on AGIO.

Sign in to join the discussion.

Scroll to Top